Literature DB >> 29731111

Kidney-targeted inhibition of protein kinase C-α ameliorates nephrotoxic nephritis with restoration of mitochondrial dysfunction.

Nino Kvirkvelia1, Malgorzata McMenamin1, Marie Warren2, Ravirajsinh N Jadeja3, Sai Karthik Kodeboyina4, Ashok Sharma4, Wenbo Zhi4, Paul M O'Connor5, Raghavan Raju2, Rudolf Lucas6, Michael P Madaio7.   

Abstract

To investigate the role of protein kinase C-α (PKC-α) in glomerulonephritis, the capacity of PKC-α inhibition to reverse the course of established nephrotoxic nephritis (NTN) was evaluated. Nephritis was induced by a single injection of nephrotoxic serum and after its onset, a PKC-α inhibitor was administered either systemically or by targeted glomerular delivery. By day seven, all mice with NTN had severe nephritis, whereas mice that received PKC-α inhibitors in either form had minimal evidence of disease. To further understand the underlying mechanism, label-free shotgun proteomic analysis of the kidney cortexes were performed, using quantitative mass spectrometry. Ingenuity pathway analysis revealed 157 differentially expressed proteins and mitochondrial dysfunction as the most modulated pathway. Functional protein groups most affected by NTN were mitochondrial proteins associated with respiratory processes. These proteins were down-regulated in the mice with NTN, while their expression was restored with PKC-α inhibition. This suggests a role for proteins that regulate oxidative phosphorylation in recovery. In cultured glomerular endothelial cells, nephrotoxic serum caused a decrease in mitochondrial respiration and membrane potential, mitochondrial morphologic changes and an increase in glycolytic lactic acid production; all normalized by PKC-α inhibition. Thus, PKC-α has a critical role in NTN progression, and the results implicate mitochondrial processes through restoring oxidative phosphorylation, as an essential mechanism underlying recovery. Importantly, our study provides additional support for targeted therapy to glomeruli to reverse the course of progressive disease.
Copyright © 2018 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PKC-α inhibition; glomerular endothelial cells; mitochondrial dysfunction; nephritis; proteomics; targeted delivery

Mesh:

Substances:

Year:  2018        PMID: 29731111      PMCID: PMC6084791          DOI: 10.1016/j.kint.2018.01.032

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  32 in total

1.  ENaC activity is increased in isolated, split-open cortical collecting ducts from protein kinase Cα knockout mice.

Authors:  Hui-Fang Bao; Tiffany L Thai; Qiang Yue; He-Ping Ma; Amity F Eaton; Hui Cai; Janet D Klein; Jeff M Sands; Douglas C Eaton
Journal:  Am J Physiol Renal Physiol       Date:  2013-12-11

2.  Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice.

Authors:  Susan Yung; Qing Zhang; Mel K M Chau; Tak Mao Chan
Journal:  Autoimmunity       Date:  2015-06-23       Impact factor: 2.815

Review 3.  Role of the mitochondrial permeability transition in myocardial disease.

Authors:  James N Weiss; Paavo Korge; Henry M Honda; Peipei Ping
Journal:  Circ Res       Date:  2003-08-22       Impact factor: 17.367

4.  Role of calcium ions in the regulation of intramitochondrial metabolism. Effects of Na+, Mg2+ and ruthenium red on the Ca2+-stimulated oxidation of oxoglutarate and on pyruvate dehydrogenase activity in intact rat heart mitochondria.

Authors:  R M Denton; J G McCormack; N J Edgell
Journal:  Biochem J       Date:  1980-07-15       Impact factor: 3.857

5.  Isolation, culture, and characterization of endothelial cells from mouse glomeruli.

Authors:  Nese Akis; Michael P Madaio
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

6.  A subgroup of murine monoclonal anti-deoxyribonucleic acid antibodies traverse the cytoplasm and enter the nucleus in a time-and temperature- dependent manner.

Authors:  K Yanase; R M Smith; B Cĭzman; M H Foster; L D Peachey; L Jarett; M P Madaio
Journal:  Lab Invest       Date:  1994-07       Impact factor: 5.662

7.  Protein kinase C-α and arginase I mediate pneumolysin-induced pulmonary endothelial hyperpermeability.

Authors:  Rudolf Lucas; Guang Yang; Boris A Gorshkov; Evgeny A Zemskov; Supriya Sridhar; Nagavedi S Umapathy; Agnieszka Jezierska-Drutel; Irina B Alieva; Martin Leustik; Hamid Hossain; Bernhard Fischer; John D Catravas; Alexander D Verin; Jean-François Pittet; Ruth B Caldwell; Timothy J Mitchell; Stephen D Cederbaum; David J Fulton; Michael A Matthay; Robert W Caldwell; Maritza J Romero; Trinad Chakraborty
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05-10       Impact factor: 6.914

8.  Dual protein kinase C alpha and beta inhibitors and diabetic kidney disease: a revisited therapeutic target for future clinical trials.

Authors:  Daisuke Koya
Journal:  J Diabetes Investig       Date:  2013-11-18       Impact factor: 4.232

9.  Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Michael P Madaio; Jeffrey V Ravetch
Journal:  J Exp Med       Date:  2006-03-06       Impact factor: 14.307

10.  Western blots versus selected reaction monitoring assays: time to turn the tables?

Authors:  Ruedi Aebersold; Alma L Burlingame; Ralph A Bradshaw
Journal:  Mol Cell Proteomics       Date:  2013-06-10       Impact factor: 5.911

View more
  2 in total

Review 1.  Novel Drug Delivery Technologies and Targets for Renal Disease.

Authors:  Alejandro R Chade; Gene L Bidwell
Journal:  Hypertension       Date:  2022-06-02       Impact factor: 9.897

2.  The Effects of Icariin on Enhancing Motor Recovery Through Attenuating Pro-inflammatory Factors and Oxidative Stress via Mitochondrial Apoptotic Pathway in the Mice Model of Spinal Cord Injury.

Authors:  Haotian Li; Xinran Zhang; Xu Zhu; Xi Qi; Kaili Lin; Liming Cheng
Journal:  Front Physiol       Date:  2018-11-16       Impact factor: 4.566

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.